
https://www.skyrizi.com/
Search...
SKYRIZI™ (risankizumab-rzaa...
Important Safety Information
Full Prescribing Information & Patient Information
Healthcare Professionals Site
Skyrizi
risankizumab-rzaa
For Adults With Moderate to Severe Plaque Psoriasis
Sign in or Register
Search
SKYRIZI RESULTS
ABOUT SKYRIZI
PLAQUE PSORIASIS
ASKING ABOUT SKYRIZI
SKYRIZI RESOURCES
STARTING SKYRIZI
THE OPPORTUNITY FOR NOTHING ON MY SKIN MEANS EVERYTHING TO ME
NOTHING IS EVERYTHING
IN CLINICAL TRIALS AT 1 YEAR, NEARLY
6 OUT OF 10 PEOPLE ACHIEVED 100% CLEAR SKIN
Also, 3 out of 4 people achieved 90% clearer skin at 4 months.
See what SKYRIZI can do
Coronavirus Update
RESULTS WITH SKYRIZI
BEFORE & AFTER PHOTOS
DOSING FOR SKYRIZI
SAVE ON SKYRIZI
USE
SKYRIZI is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).
IMPORTANT SAFETY INFORMATION
SKYRIZI may cause serious side effects, including infections. SKYRIZI is a prescription medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during

Share your SKYRIZI story

Share your experience with SKYRIZI to help inform and inspire others. To participate, please email us at info@SPEAKnetwork.net or call 877-861-6180.

Understanding plaque psoriasis

What it is. What it isn't. What to know about it, from diagnosis to treatment.

Find out more ▸

Your dedicated Nurse Ambassador*

Your Skyrizi Complete Nurse Ambassador is committed to getting to know you and your individual SKYRIZI needs.

Get to know the Nurse Ambassador ▸

*Nurse Ambassadors do not give medical advice and will direct you to your healthcare professional for any treatment-related questions, including further referrals.

Coronavirus Update

USE

SKYRIZI is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).

IMPORTANT SAFETY INFORMATION

SKYRIZI may cause serious side effects, including infections. SKYRIZI is a prescription medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI. Tell

USE

SKYRIZI is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SKYRIZI™ (risankizumab-rzaa)?

SKYRIZI may cause serious side effects, including infections. SKYRIZI is a prescription medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.

- Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
  - fever, sweats, or chills
  - muscle aches
  - weight loss
  - cough
  - warm, red, or painful skin or sores on your body different from your psoriasis
  - diarrhea or stomach pain
  - shortness of breath
  - blood in your mucus (phlegm)
  - burning when you urinate or urinating more often than normal

Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:

- have any of the conditions or symptoms listed in the section "What is the most important information I should know about SKYRIZI?"
- have an infection that does not go away or that keeps coming back.
- have TB or have been in close contact with someone with TB.
- have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with SKYRIZI.
- are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SKYRIZI?



What are the possible side effects of SKYRIZI?

SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?"

The most common side effects of SKYRIZI include upper respiratory infections, fungal skin infections, headache, feeling tired, and injection site reactions.

These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

US-RISN-180038

Please see the **Full Prescribing Information**, including the **Medication Guide**, for SKYRIZI.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help.
Visit AbbVie.com/myAbbVieAssist to learn more.

US-SKZ-200020

US-RISN-180038

Please see the **Full Prescribing Information**, including the **Medication Guide**, for SKYRIZI.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help.
Visit AbbVie.com/myAbbVieAssist to learn more.

US-SKZ-200020


SKYRIZI™ (risankizumab-rzaa): ...
SKYRIZI (risankizumab-rzaa) ...
Skyrizi
risankizumab-rzaa
75mg/0.83mL Injection
FOR HEALTHCARE PROFESSIONALS
HOME
CLINICAL EFFICACY
DOSING
CLINICAL SAFETY
ACCESS
SUPPORT & RESOURCES
The IL-23 inhibitor from AbbVie indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Nothing less than the opportunity for durable skin clearance; for your patients, that's everything
NOTHING IS EVERYTHING
COVID-19 Update
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI™ (risankizumab-rzaa)
Infection
SKYRIZI™ may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.
Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with


https://www.skyrizihcp.com/
Search...
SKYRIZI™ (risankizumab-rzaa): ...
SKYRIZI (risankizumab-rzaa) ...
DURABLE.
Most patients achieved PASI 90 at Week 16 and maintained it at Week 52[12]
VIEW TRIALS
RAPID.
Co-primary endpoints of PASI 90 and sPGA 0/1 at Week 16, including improvement 4 weeks after 1st dose[13]
VIEW TRIALS
CLEAR.
The majority of patients achieved PASI 100 at Week 52[12]
VIEW TRIALS
4 DOSES PER YEAR.
3-month dosing after 2 initiation doses at Weeks 0 and 4 (150 mg/dose)
VIEW DOSING
Nothing less than a commitment to working toward
100% COMMERCIAL PATIENT ACCESS
VIEW ACCESS
PASI 90=≥90% improvement in Psoriasis Area and Severity Index;
PASI 100=100% improvement in Psoriasis Area and Severity Index;
sPGA 0/1=static Physician's Global Assessment rating of clear or almost clear.
COVID-19 Update
T WEEK 16:
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI™ (risankizumab-rzaa)
Infection
SKYRIZI™ may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.
Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB

SKYRIZI™ (risankizumab-rzaa): ... | SKYRIZI (risankizumab-rzaa) ...

AT WEEK 16[1]:

75% OF SKYRIZI PATIENTS

(n=294)

ACHIEVED PASI 90

in the UltIMMa-2 study vs 2% placebo (n=98) patients

84% of SKYRIZI patients achieved sPGA 0/1 vs 5% placebo patients

UltIMMa-1 results at Week 16
PASI 90: SKYRIZI 75% (n=304), placebo 5% (n=102)
sPGA 0/1: SKYRIZI 88% (n=304), placebo 8% (n=102)

Co-primary endpoints for UltIMMa-1 and -2 were PASI 90 and sPGA 0/1 response vs placebo at Week 16.

P<0.001 for comparisons of SKYRIZI vs placebo

STUDY DESIGN:

MMa-1 (N=506) and UltIMMa-2 (N=491) were replicate phase 3, randomized, double-blind, ebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) lacebo over 16 weeks and biologic active control over 52 weeks in adult patients with **derate to severe plaque psoriasis.**[12]

W STUDY DESIGN AND BASELINE CHARACTERISTICS ›

COVID-19 Update

SEE CLINICAL TRIAL RESULTS INCLUDING PASI 100 DATA →

IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI™ (risankizumab-rzaa)[1]

Infection

SKYRIZI™ may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB

SEE CLINICAL TRIAL RESULTS INCLUDING PASI 100 DATA →

AT WEEK 52[1]:

81% OF SKYRIZI PATIENTS

(n=294)

ACHIEVED PASI 90

in the UltIMMa-2 study; placebo did not continue beyond Week 16

UltIMMa-1 results at Week 52
PASI 90: SKYRIZI 82% (n=304), placebo n/a

Co-primary endpoints for UltIMMa-1 and -2 were PASI 90 and sPGA 0/1 response vs placebo at Week 16.

P<0.001 for comparisons of SKYRIZI vs placebo

STUDY DESIGN:

UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control over 52 weeks in adult patients with **moderate to severe plaque psoriasis**.[1]

VIEW STUDY DESIGN AND BASELINE CHARACTERISTICS ›

COVID-19 Update

SEE CLINICAL TRIAL RESULTS INCLUDING PASI 100 DATA →

IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI™ (risankizumab-rzaa)[1]

Infection

SKYRIZI™ may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with



IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI™ (risankizumab-rzaa)

Infection

SKYRIZI™ may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with

SKYRIZI™ (risankizumab-rzaa): ... | SKYRIZI (risankizumab-rzaa) ...

NOTHING LESS THAN A COMMITMENT TO WORKING TOWARD

100% COMMERCIAL PATIENT ACCESS

Skyrizi™ COMPLETE

Eligible patients may be able to access their SKYRIZI at no charge until their insurance plan covers SKYRIZI

VIEW SKYRIZI COMPLETE →

COVID-19 Update

IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI™ (risankizumab-rzaa)①

Infection

SKYRIZI™ may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with

Nothing less than a commitment to working toward

100% COMMERCIAL PATIENT ACCESS

VIEW ACCESS

COVID-19 Update

IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI™ (risankizumab-rzaa) [1]

Indication

SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Important Safety Information

Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

site reactions, and tinea infections.

Please see Full Prescribing Information.

US-SKZD-190350

REFERENCES

1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
2. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. *Lancet.* 2018;392(10148):650-661.
3. Lebwohl M, Bachelez H, Valdecantos WC, Wu T, Gordon K. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis: an integrated analysis of UltIMMa-1 and UltIMMa-2. Poster presented at: American Academy of Dermatology Annual Meeting; March 1-5, 2019; Washington, DC.

US-SKZD-190271

abbvie